All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @michlivinlife on TikTok · 127s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @michlivinlife's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Well, I am one month post-partum and I am getting back on the shot today and I'm so excited about it.
  2. 0:05If you don't know about me, I lost 175 LBS, um, I don't know, over the past three years, four years,
  3. 0:13whatever, what combination of the click click and also, um, gastric sleeve surgery. And I just had
  4. 0:20triplet, so I gained literally 120 pounds and insane. But then as soon as I have, uh, had them,
  5. 0:26I lost 60, 70 pounds. I don't know, but right now I weigh 256 pounds. So my goal is to get back
  6. 0:33to my pre-pregnancy weight, which I weighed like 185, 186. So we have a lot to lose. Okay.
  7. 0:41I haven't had to lose as much weight since I started my journey four years ago. Okay, I don't know
  8. 0:45what to do. I mean, I do know what to do. I just like can't go to the gym right now because I
  9. 0:49literally had a C section with three kids. So, um, I can't do anything yet. But my prescription
  10. 0:55just got sent to the pharmacy. I'm really, really excited. I love the way I feel when I'm on it.
  11. 1:00A lot of people are like, Oh, I don't like the side effects on it like this. If you eat and do
  12. 1:05all the right things and drink your water and like your exercising, you're doing all the things,
  13. 1:08like it goes away. It literally stops. And I'm so, so, so, so excited to start the inflammation,
  14. 1:15just like the quietness of my brain. My brain's so loud right now. And I'm ready for it to shut
  15. 1:20off for a minute again. And apparently that side effect is in people that like have ADHD if they
  16. 1:24take the medication just feels quiet in their head for once. I feel like for me, it really works.
  17. 1:29Very thrilled about that. Very thrilled to get back my old clothes right now. I'm wearing extra
  18. 1:33large again and everything, which there's no problem with that. But it's just like uncomfortable and
  19. 1:37annoyingly enough, I threw out all of my clothes right before I got pregnant. So I have nothing that
  20. 1:42fits me besides new things. I have to buy. And since I have triplets, I really don't have that much
  21. 1:46money to spare because I'm spending so much money on formula and diapers. Okay, maybe I can
  22. 1:51cheap it out, not by coterie diapers and not buy the expensive formula, but mommy's gonna do what
  23. 1:56mommy's gonna do. Anyway, let me know. Have you ever had to start all over again? This is my first
  24. 2:00time. I really was great about being a maintenance and now I'm starting all over. Okay, love you.
  25. 2:06Love ya. See ya. Bye.

Restarting Zepbound after pregnancy: what the science says about GLP-1 regain

michaela pearson 💗✨

TikTok creator

29.4K viewsWatch on TikTok

Quick answer

The creator is restarting tirzepatide (Zepbound) one month after a C-section delivery of triplets, having previously lost 175 pounds using tirzepatide combined with gastric sleeve surgery. She gained approximately 120 pounds during the triplet pregnancy and is now approximately 70 pounds above her pre-pregnancy weight. No mention is made of breastfeeding status, which is clinically relevant given the absence of human lactation safety data for tirzepatide in the current prescribing information.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded TirzepatideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Tirzepatide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Restarting Zepbound after pregnancy: what the science says about GLP-1 regain, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this tirzepatide video claims cluster

Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Restarting Zepbound after pregnancy: what the science says about GLP-1 regain" from michaela pearson 💗✨. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is restarting tirzepatide (Zepbound) one month after a C-section delivery of triplets, having previously lost 175 pounds using tirzepatide combined with gastric sleeve surgery.

The reason this review is not generic is the source wording and the canonical claim label "glp1 getting back on the zep super excited but scared to start al." In this clip, the useful excerpt is: "Well, I am one month post-partum and I am getting back on the shot today and I'm so excited about it." That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

The 'food noise' quieting effect is real and documented in appetite-suppression data across SURMOUNT and SCALE trials, but its specific relationship to ADHD is still early-stage and observational, not confirmed in randomized trials.
People who land here are usually comparing the Compounded Tirzepatide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Tirzepatide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator is restarting tirzepatide (Zepbound) one month after a C-section delivery of triplets, having previously lost 175 pounds using tirzepatide combined with gastric sleeve surgery.

FormBlends verdict

Compounded Tirzepatide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator is restarting tirzepatide (Zepbound) one month after a C-section delivery of triplets, having previously lost 175 pounds using tirzepatide combined with gastric sleeve surgery. She gained approximately 120 pounds during the triplet pregnancy and is now approximately 70 pounds above her pre-pregnancy weight. No mention is made of breastfeeding status, which is clinically relevant given the absence of human lactation safety data for tirzepatide in the current prescribing information.
  • Tirzepatide's GI side effects are dose-dependent and receptor-mediated. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed roughly 30% nausea rates that cannot be reliably prevented by hydration or diet alone.
  • The 'food noise' quieting effect is real and documented in appetite-suppression data across SURMOUNT and SCALE trials, but its specific relationship to ADHD is still early-stage and observational, not confirmed in randomized trials.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.

Review Compounded Tirzepatide

What You'll Learn

  • Tirzepatide's GI side effects are dose-dependent and receptor-mediated. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed roughly 30% nausea rates that cannot be reliably prevented by hydration or diet alone.
  • The 'food noise' quieting effect is real and documented in appetite-suppression data across SURMOUNT and SCALE trials, but its specific relationship to ADHD is still early-stage and observational, not confirmed in randomized trials.
  • Immediate postpartum weight loss of 60-70 pounds after a triplet delivery reflects normal obstetric physiology, including fetal weight, placenta, and fluid shifts, not a medication head start.
  • The Zepbound prescribing label (Eli Lilly, 2023) does not include human lactation safety data. Anyone breastfeeding should discuss this explicitly with their prescriber before restarting.
  • Weight regain after stopping GLP-1 therapy is well-documented. A 2022 study by Wilding et al. in Diabetes, Obesity and Metabolism showed participants regained roughly two-thirds of lost weight within one year of stopping semaglutide.
  • C-section recovery involves ongoing healing of uterine and fascial tissue. Tirzepatide's appetite suppression can significantly reduce protein and caloric intake at a time when postpartum tissue repair requires adequate nutrition.
  • Combining GLP-1 therapy with prior bariatric surgery is a real clinical scenario, but one with limited published long-term outcome data. Patients in this situation need closer prescriber monitoring, not social media timelines.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @michlivinlife actually say?

One month after a C-section delivery of triplets, @michlivinlife announced she's restarting tirzepatide (Zepbound). She described gaining 120 pounds during pregnancy and losing 60-70 pounds immediately postpartum, putting her current weight at 256 pounds with a goal of returning to roughly 185 pounds. She also claimed that side effects from GLP-1 medications largely disappear "if you eat and do all the right things," and that tirzepatide produces a "quietness" in people with ADHD specifically. These are the claims worth examining.

For context, she previously lost 175 pounds over about four years using a combination of tirzepatide and gastric sleeve surgery. This is not someone new to weight loss medicine. That history matters when evaluating what she says.

Does the science back this up?

Partially. The ADHD-quietness claim has real signal behind it, but she overstates the certainty. The side-effect-management claim is more complicated than she makes it sound.

On the ADHD angle: there's emerging observational data suggesting GLP-1 receptor agonists may reduce impulsivity and "food noise" in ways that overlap with ADHD symptom profiles. A 2024 study by Erritzoe et al. in eClinicalMedicine found that semaglutide users self-reported reductions in compulsive behaviors and cognitive hyperactivity. But this is still early-stage research, not a replicated clinical finding. The mechanism, likely dopaminergic signaling in the nucleus accumbens, is plausible, but it has not been confirmed in randomized controlled trials specific to ADHD populations.

On side effects resolving with good habits: the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed that nausea and GI side effects are dose-dependent and often time-limited, but they are not reliably controlled by hydration or diet alone. This framing could discourage people from reporting persistent side effects to their prescriber.

What did they get wrong (or right)?

She got the general experience right. She got the mechanism oversimplified.

The claim that side effects "literally stop" if you "drink your water" and "do all the right things" is misleading. GI side effects from tirzepatide, including nausea and vomiting, are primarily driven by the drug's action on GIP and GLP-1 receptors in the gut, not by patient behavior. While eating slowly and avoiding high-fat meals can reduce severity, they do not reliably prevent side effects. Telling new users that side effects are essentially their own fault if they persist is not accurate and could lead people to dismiss real tolerability problems.

What she got right: the "food noise" description is one of the more honest characterizations of how GLP-1 medications feel to patients who respond well. The SCALE and SURMOUNT trials consistently documented appetite suppression as a central mechanism. Her description of restarting after significant weight regain during pregnancy is also clinically realistic, not fear-mongering.

  • Side effects: misleading framing, real phenomenon
  • ADHD quietness: plausible but overstated certainty
  • Weight regain after stopping: completely consistent with clinical data

What should you actually know?

Restarting tirzepatide at one month postpartum raises real clinical questions she does not address, and anyone considering this should know them.

First, the prescribing guidance for tirzepatide (Zepbound label, Eli Lilly, 2023) does not include studied safety data for women who are breastfeeding. The drug is excreted into breast milk in animal studies. She does not mention whether she is breastfeeding, but anyone who is should discuss this explicitly with their prescriber, not follow a TikTok timeline.

Second, C-section recovery at one month postpartum involves ongoing healing of the uterine incision and abdominal fascia. Tirzepatide's appetite suppression can substantially reduce caloric and protein intake. In postpartum recovery, that matters. There is no published trial data on tirzepatide use in the immediate postpartum period specifically.

Third, the weight she lost immediately after delivery, roughly 60-70 pounds, is largely explained by delivery of the fetuses, placenta, amniotic fluid, and postpartum fluid shifts, not medication. That is normal physiology, not a head start on weight loss.

Bottom line

This creator has legitimate firsthand experience with tirzepatide and is sharing it honestly. But "do all the right things and side effects go away" is not what the clinical data shows, and the ADHD claim needs a much larger asterisk than she gives it. The postpartum timing question is the most important thing missing from this video entirely.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

michaela pearson 💗✨ · TikTok creator

29.4K views on this video

Getting back on the Zep. Super excited but scared to start all over. Have you ever had to? #zepbound #pregnancy #regain #postpartum #snapback

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about tirzepatide's gi side effects?

Tirzepatide's GI side effects are dose-dependent and receptor-mediated. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed roughly 30% nausea rates that cannot be reliably prevented by hydration or diet alone.

What does the video say about the 'food noise' quieting effect?

The 'food noise' quieting effect is real and documented in appetite-suppression data across SURMOUNT and SCALE trials, but its specific relationship to ADHD is still early-stage and observational, not confirmed in randomized trials.

What does the video say about immediate postpartum weight loss of 60-70 pounds after a triplet?

Immediate postpartum weight loss of 60-70 pounds after a triplet delivery reflects normal obstetric physiology, including fetal weight, placenta, and fluid shifts, not a medication head start.

What does the video say about the zepbound prescribing label (eli lilly, 2023) does not include?

The Zepbound prescribing label (Eli Lilly, 2023) does not include human lactation safety data. Anyone breastfeeding should discuss this explicitly with their prescriber before restarting.

What does the video say about weight regain after stopping glp-1 therapy?

Weight regain after stopping GLP-1 therapy is well-documented. A 2022 study by Wilding et al. in Diabetes, Obesity and Metabolism showed participants regained roughly two-thirds of lost weight within one year of stopping semaglutide.

What does the video say about c-section recovery involves ongoing healing of uterine?

C-section recovery involves ongoing healing of uterine and fascial tissue. Tirzepatide's appetite suppression can significantly reduce protein and caloric intake at a time when postpartum tissue repair requires adequate nutrition.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by michaela pearson 💗✨, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.